Resources
57 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/12/2024
Researchers used data from electronic license renewals in 2021 to examine what factors affect the likelihood of providing medication-assisted treatment (MAT) for opioid use disorder. Physicians and nurse practitioners who were younger, practiced in a public or community health center, and offered a sliding fee scale in their practice had a greater likelihood of providing MAT.
Posted 1/26/2024 (updated 3/28/2024)
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 2/21/2023 (updated 3/27/2024)
The report provides key findings from the study assessing substance use and recovery stigma by healthcare workers, compared to non-healthcare workers. The stigma that is perceived by people who use drugs or are in recovery (PWUD/IR) was found to be a structural concern as a large population are opting out of going to the doctor, leaving them open to a variety of untreated illnesses.
Posted 1/24/2023 (updated 3/27/2024)
Clinicians no longer need DATA 2000 Waiver training to prescribe buprenorphine; however, the payment program to defray earlier training costs is still active. Launched in June 2021, the initiative pays for providers who previously received a waiver to prescribe buprenorphine, a medication used to treat opioid use disorder. Rural Health Clinics (RHCs) still have the opportunity to apply for a $3,000 payment on behalf of each provider who previously trained to obtain the waiver necessary to prescribe buprenorphine after January 1, 2019.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 8/17/2022 (updated 3/27/2024)
The National Advisory Committee on Rural Health and Human Services recently published a policy brief on behavioral health and primary care integration in rural health facilities.
Posted 6/27/2022 (updated 3/27/2024)
The U.S. Department of Housing and Urban Development (HUD) announced a broad, new initiative to connect individuals and families to housing, health care, and supportive services. Total funding of $322 million is a supplement to HUD’s Continuum of Care (CoC) Program, with $43 million for incremental housing vouchers for at-risk households, and $54 million set aside for projects in rural areas.
Posted 4/20/2022 (updated 3/27/2024)
This updated (March 2020) TIP is intended to provide addiction counselors and other providers, supervisors, and administrators with the latest science in the screening, assessment, diagnosis, and management of co-occurring disorders (CODs).
Posted 3/24/2022 (updated 3/27/2024)
If you received specific disposal instructions from your healthcare provider (e.g., doctor, pharmacist) for your unused or expired medicine, you should follow those instructions to dispose of your medicine. The best disposal option is to find a drug take back location, which may be found in retail, hospital, or clinic pharmacies; and/or law enforcement facilities.